A5101601267- Retinal Diseases and Treatments
- Retinal and Macular Surgery
- Retinal and Optic Conditions
- Intraocular Surgery and Lenses
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
- Vascular Malformations Diagnosis and Treatment
- Ocular Diseases and Behçet’s Syndrome
- Retinal Development and Disorders
- Corneal surgery and disorders
- Ophthalmology and Visual Impairment Studies
- Sinusitis and nasal conditions
- Ocular Infections and Treatments
- Corneal Surgery and Treatments
- Drug-Induced Ocular Toxicity
- Healthcare Systems and Challenges
- Mosquito-borne diseases and control
- Yersinia bacterium, plague, ectoparasites research
- Ocular Surface and Contact Lens
- Medical and Biological Sciences
- Viral Infections and Vectors
- Optical Coherence Tomography Applications
- Antioxidant Activity and Oxidative Stress
- Global Healthcare and Medical Tourism
- Veterinary Practice and Education Studies
Loma Linda University
2015-2024
Southern California Desert Retina Consultants
2014-2024
Bridge University
2019
California Retina Consultants
2018
VA Greater Los Angeles Healthcare System
2016
Doheny Eye Institute
2016
Black Hills Regional Eye Institute
2016
University of California, Los Angeles
2016
Cleveland Eye Clinic
2007-2010
Cleveland Clinic
2007-2010
Error in Figure in: A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated Macular Edema Secondary Central Retinal Vein Occlusion: Standard Care vs Corticosteroid for Occlusion (SCORE) Study Report 5
After the Age-Related Eye Disease Study 2 (AREDS2) study, beta carotene component was replaced by lutein/zeaxanthin for development of revised AREDS supplement. However, it is unknown if increased risk lung cancer observed in those assigned persists beyond conclusion AREDS2 trial and there a benefit adding to original supplement that can be with long-term follow-up.To assess 10-year developing late age-related macular degeneration (AMD).This multicenter epidemiologic follow-up study clinical...
To study retinal pigment epithelium (RPE) tears after off-label intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injection for neovascular age-related macular degeneration. Eyes with a vascularized epithelial detachment (PED) that developed an RPE tear were compared eyes PED but without tear.Nine retina specialists across the United States and in Europe participated this retrospective case series. All received choroidal neovascularization (CNV) over 12 months...
Purpose: To report 1-year follow-up of a phase 1/2a clinical trial testing composite subretinal implant having polarized human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells on an ultrathin parylene substrate in subjects with advanced non-neovascular age-related macular degeneration (NNAMD) Methods: The included 16 two cohorts. main endpoint was safety assessed at 365 days using ophthalmic and systemic exams. Pseudophakic geographic atrophy (GA) severe vision loss...
The purpose was to study preinjection optical coherence tomography-related factors in age-related macular degeneration eyes with retinal pigment epithelial detachment (PED) that may predispose (RPE) tears associated intravitreal bevacizumab injections.This multicenter retrospective case series involving 9 retina specialists and 7 centers investigated Stratus tomography (Carl Zeiss Meditec, Dublin, CA) parameters vascularized PED (vPED) from February 2006 2007. Of the 1,280 1,255 patients...
To prospectively determine the incidence and risk factors for retinal pigment epithelial (RPE) tears in eyes with vascularized detachments (PED) exudative age-related macular degeneration receiving antivascular endothelial growth factor therapy.Eyes were randomized into 1 of 4 arms: 1) 0.5 mg ranibizumab monthly 12 months; 2) 3 months then pro re nata on basis clinical optical coherence tomography-guided indications; 3) high-dose 2.0 or 4) thereafter. All PEDs measured height, greatest...
Cell-based therapies face challenges, including poor cell survival, immune rejection, and integration into pathologic tissue. We conducted an open-label phase 1/2a clinical trial to assess the safety preliminary efficacy of a subretinal implant consisting polarized monolayer allogeneic human embryonic stem cell-derived retinal pigmented epithelium (RPE) cells in subjects with geographic atrophy (GA) secondary dry age-related macular degeneration. Postmortem histology from one subject very...
To evaluate the outcome of perfluoropropane (C3F8) gas injection for symptomatic vitreomacular traction (VMT) with or without Stage 2 macular hole (MH).A retrospective review eyes VMT treated 0.3 mL C3F8 was performed. Patients avoided supine position until resolution. small MH maintained partial face-down positioning.Forty-nine consecutive patients (50 eyes) underwent pneumatic vitreolysis between 2010 and 2016. A posterior vitreous detachment developed in 43 (86.0%) after a single...
To evaluate the response to aflibercept therapy for Type 1 and 3 neovascularization in pigment epithelial detachments associated with treatment-naive, neovascular age-related macular degeneration.In this multicentered, prospective study, eligible eyes underwent an intravitreal injection protocol 12 months. Visual acuity morphologic features of were compared at baseline follow-up intervals between versus neovascularization.Thirty-six analyzed. At months, lesions showed a 4.5 ± 23 Early...
Purpose To describe the unusual complication of retinal pigment epithelial (RPE) tear after intravitreal ranibizumab (Lucentis ® ) for subfoveal fibrovascular detachment (PED) and its effective management. Methods Chart review case report RPE ranibizumab. Results An inferior was documented by fluorescein angiography, fundus photography, optical coherence tomography (OCT) 1 month receiving repeat injection in right eye a patient with bilateral PED. He had undergone multiple bevacizumab...